The 2016 application deadline has passed. The 2017 program will open March 13, 2017
Gilead
 
Funding Considerations


Gilead Research Fellowship Program

If you are selected as an award recipient, you and your institution must agree to the following items, including, but not limited to:

  • Exclusive Use of Funding

    In an effort to maximize the research benefit of the award, indirect costs paid under this Program may not exceed 8% of the award and are included as part of the budget, not as an addition to the value of the award.


  • Use of Gilead Product

    Proposals utilizing Gilead product(s) are not eligible for funding through the Research Scholars Program. Proposals involving Gilead product(s) should be submitted for review under the Investigator Sponsored Research Grant Program through our online portal: http://www.gilead.com/research/investigator-sponsored


  • Progress Reports

    Submission of research progress and financial accounting reports for review by the Committee are required annually. Funding for the second year is contingent upon Committee Chair approval of the research progress report.


  • Publications

    The support of the Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension must be acknowledged in any publication or abstracts resulting from research funded by this award.


  • Intellectual Property

    The host institution shall retain ownership of inventions made by the institution and investigator during the conduct of the research.


  • Change of Institution or Discontinuation

    The Research Scholars Program Coordinator must be notified immediately if the award recipient leaves the host institution or discontinues the research funded by the Program. In the event award recipient moves to another institution, the award may be transferred at the sole discretion of the Committee. The new host institution must also agree to accept the terms and conditions of the existing award. In the event the host institution or award recipient is unable or desires to discontinue the research before its completion, institution will be required to return all uexpended funds and any remaining award will be terminated.

Award recipients and their institutions will be required to enter into a written grant agreement with Gilead prior to receipt of funding.